EASL 2012 Report – EMERGE: Efficacy and safety in HCV of investigative pegylated interferon lambda-1a compared to standard interferon therapy
by Bruce Sylvester – Researchers report that patients with genotype 2 or 3 hepatitis C virus (HCV) treated with investigative pegylated interferon lambda-1a (peg-IFN-lambda 1a, Bristol-Myers Squibb) in… read more.